Imatinib mesylate--a new oral targeted therapy

N Engl J Med. 2002 Feb 28;346(9):683-93. doi: 10.1056/NEJMra013339.
No abstract available

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Clinical Trials as Topic
  • Drug Resistance
  • Gastrointestinal Neoplasms / drug therapy*
  • Humans
  • Hydroxyurea / economics
  • Hydroxyurea / therapeutic use
  • Imatinib Mesylate
  • Interferon-alpha / economics
  • Interferon-alpha / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Piperazines / economics
  • Piperazines / therapeutic use*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Pyrimidines / economics
  • Pyrimidines / therapeutic use*
  • Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors
  • Sarcoma / drug therapy*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Interferon-alpha
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Receptors, Platelet-Derived Growth Factor
  • Hydroxyurea